Clinical trials: Complication of Treatment
Radical Prostatectomy, Stress Urinary Incontinence (SUI)
Pivotal Study of Voro Urologic Scaffold
The objective of this study is to compare safety and effectiveness of the Voro Urologic Scaffold in adult men undergoing robotic assisted radical prostatectomy as compared to control arm.
- Trial name
- ARID II (NCT06873581)
- Testing
- Voro Urologic Scaffold
- Where
- 19 sites in United States
- Volunteers
- 266 people
- Sponsor
- Levee Medical, Inc.
Urinary Incontinence , Stress
Monocentric Pilot Study for the Application of an Endourethral Device for the Treatment of Stress Urinary Incontinence
Stress urinary incontinence is defined as the involuntary loss of urine during exertion or physical activity (i.e., sports) or during sneezing or coughing.
- Trial name
- CIP-003 (NCT07327528)
- Testing
- UroRelief, a sterile, single-use, endourethral medical device suitable for both men and women, which is positioned at the bladder neck for the treatment of stress incontinence.
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Relief srl
Ureteric Stone, Stone Ureter
Semi-rigid Ureteroscopy Versus Flexible Ureteroscopy For the Treatment of Proximal Ureteric Stone
The present study is randomized in nature, comparing the stone free rate and complications rate between semi-rigid ureteroscopy (SR-URS) and Flexible Ureteroscopy (F-URS) for the treatment of Proximal Ureteric stone (PUS)…
- Trial name
- NCT04851171
- Testing
- Flexible Ureteroscopy, Semi-rigid Ureteroscopy
- Where
- Qatar
- Volunteers
- 140 people
- Sponsor
- Hamad Medical Corporation
Anemia, Renal Failure, Chronic Renal Failure
Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency
The purpose of the study is to assess the effect of an early and complete correction of anemia after treatment with epoetin alfa on the rate of progression of chronic renal failure (which involves improper functioning of the…
- Trial name
- NCT00312871
- Testing
- Epoetin alfa
- Volunteers
- 217 people
- Sponsor
- Janssen Cilag S.A.S.
Advanced Parkinson's Disease
An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications
This is an extension study to evaluate the long-term safety and tolerability of ABT-SLV187 in subjects with advanced Parkinson's disease.
- Trial name
- NCT02082249
- Testing
- ABT-SLV187
- Where
- 7 sites in Japan, South Korea and 1 more
- Volunteers
- 30 people
- Sponsor
- AbbVie
Non-Muscle Invasive Bladder Cancer (NMIBC)
Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment
A Phase Ib, open label, non randomized study to measure the safety and PK characteristics of APL-1202 at steady-state in adult male and female BCG resistant NMIBC patients when it is administered alone and concurrently with BCG.
- Trial name
- NMIBC (NCT03672240)
- Testing
- APL-1202
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Asieris Pharmaceutical Technologies Co., Ltd.
Obesity
Effects of Two Hypocaloric Diets on Weight Loss
The investigators evaluated whether an energy-restricted protein diet with low glycaemic index carbohydrates and soluble fibers (LC-P-LGI) would be more effective than a conventional diet (LC-CONV) on weight-loss and related…
- Trial name
- NCT01312740
- Testing
- LC-P-LGI diet, LC-CONV
- Where
- France
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Ceprodi S.A. Kot
Hallux Valgus
A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo
The purpose of this study is to evaluate the analgesic efficacy and safety of tapentadol immediate-release (IR [CG5503]) for use in the relief of moderate to severe acute pain, compared with placebo, in adult Taiwanese patients…
- Trial name
- NCT01813890
- Testing
- Tapentadol IR 50 mg, Tapentadol IR 75 mg
- Where
- 3 sites in Taiwan
- Volunteers
- 60 people
- Sponsor
- Janssen-Cilag International NV
Diabetic Macular Edema (DME)
A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema
The purpose of this study is to learn about the effects of BGE-102 on change in vision in participants with center-involved diabetic macular edema (CI-DME).
- Trial name
- QUELL-DME (NCT07812090)
- Testing
- Oral BGE-102, Anti-VEGF
- Where
- 16 sites in United States
- Volunteers
- 180 people
- Sponsor
- BioAge Labs, Inc.
Adenocarcinoma, Ovarian Neoplasms
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
2.0 Study Objectives: 2.1 To evaluate the ability of the MiCK assay to predict the outcome of chemotherapy of cancer patients for first-line treatment.
- Conditions
- Adenocarcinoma, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT00443196
- Testing
- MiCK Assay
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Pierian Biosciences
Urinary Incontinence,Stress, Urinary Incontinence, Urge
RCT on Multimodal Self-treatment for Women With Incontinence Using a Digital Health Application
This study, titled "Prospective Randomized Study on Multimodal Self-Treatment for Women with Incontinence Symptoms Using a Digital Health Application," abbreviated as DINKS, aims to investigate the efficacy of a digital health…
- Conditions
- Urinary Incontinence,Stress, Urinary Incontinence, Urge, Urinary Incontinence, Overactive Bladder Syndrome
- Trial name
- DINKS (NCT06389838)
- Testing
- Kranus Mictera
- Where
- Germany
- Volunteers
- 194 people
- Sponsor
- Kranus Health GmbH
Schistosoma Hematobium Infection, Schistosomiasis Mansoni
Safety and Efficacy of Mirazid for Schistosomiasis Treatment
Clinical Trial Phase:Phase III Primary Objectives: Compare Mirazid and Praziquantel cure rates for both Schistosoma species. Compare Mirazid and Praziquantel effect in lowering the intensity of infection for both Schistosoma…
- Trial name
- PHAR0211 (NCT01529710)
- Testing
- Myrrh
- Where
- 2 sites in Egypt
- Volunteers
- 200 people
- Sponsor
- Pharco Pharmaceuticals
End Stage Kidney Disease, End Stage Renal Disease
Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study
Retrospective, multicenter, comparative, post-market study of the Tablo Hemodialysis System in hospitalized participants with End-Stage Renal Disease or Acute Kidney Injury.
- Conditions
- End Stage Kidney Disease, End Stage Renal Disease, Acute Kidney Injury
- Trial name
- COMPARE (NCT04912024)
- Testing
- Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System, Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems
- Where
- 2 sites in United States
- Volunteers
- 458 people
- Sponsor
- Outset Medical
Chronic Kidney Disease
Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease
The objective of this study was to evaluate the efficacy of HRS-1780 tablets or Henagliflozin Proline tablets in patients with chronic kidney disease by evaluating UACR change from baseline to Week 13
- Trial name
- NCT06221059
- Where
- China
- Volunteers
- 181 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Ovarian Cancer, Ovarian Neoplasms
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy.
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT07776691
- Testing
- R-DXd, Bevacizumab
- Where
- 11 sites in United States, Israel and 2 more
- Volunteers
- 802 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Cancer
A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
IMP4297 is a PARP inhibitor. This is a 2:1 randomized, double-blind, placebo-controlled study conducted in patients with advanced (FIGO Stage III or IV) ovarian cancer to evaluate Efficacy and Safety of IMP4297 for Maintenance…
- Trial name
- FLAMES (NCT04169997)
- Testing
- IMP4927
- Where
- 2 sites in China
- Volunteers
- 404 people
- Sponsor
- Impact Therapeutics, Inc.
Menorrhagia, Heavy Menstrual Bleeding
Minitouch Endometrial Ablation System Treatment for Menorrhagia: An Evaluation of Safety & Effectiveness
The EASE Clinical Trial is prospective, multi-center, single-arm (open-label), non-randomized, clinical trial to evaluate the Minitouch Endometrial Ablation System ("Minitouch System") in premenopausal women with menorrhagia.
- Conditions
- Menorrhagia, Heavy Menstrual Bleeding, Heavy Uterine Bleeding
- Trial name
- NCT04267562
- Testing
- Minitouch System
- Where
- 5 sites in United States
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- MicroCube, LLC
Chronic Kidney Disease, Diabetic Nephropathy
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study. The objective of the study is to evaluate the efficacy and safety of once daily administration of atrasentan tablets (low dose and high dose) compared…
- Trial name
- RADAR (NCT01356849)
- Testing
- Atrasentan
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 149 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Fabry Disease
A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects with Fabry Disease and Amenable GLA Variants and Severe Renal Impairment (SRI) or End Stage Renal Disease (ESRD)
- Trial name
- NCT04020055
- Testing
- migalastat HCl 150 mg
- Where
- 12 sites in United States, Australia and 4 more
- Volunteers
- 14 people
- Sponsor
- Amicus Therapeutics
Breast Cancer and Ovarian Cancer
Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer
This was a randomized, multi centre, open label, two treatment, two period, two sequence, single dose, crossover study, with at least 28 days washout between doses, conducted under fed (normal breakfast) conditions.
- Trial name
- NCT03055143
- Testing
- SPARC-08-038, Ref-08-038
- Volunteers
- 29 people
- Sponsor
- Sun Pharma Advanced Research Company Limited